Advertisement


Marie Plante, MD, on Cervical Cancer: New Data on Hysterectomy and Pelvic Node Dissection

2023 ASCO Annual Meeting

Advertisement

Marie Plante, MD, of Canada’s Université Laval and the CHUQ Hotel Dieu de Québec, discusses phase III results from a study that compared radical hysterectomy and pelvic node dissection vs simple hysterectomy and pelvic node dissection in patients with low-risk early-stage cervical cancer. The pelvic recurrence rate at 3 years in the women who underwent simple hysterectomy is not inferior to those who had radical hysterectomy. In addition, fewer surgical complications and better quality of life were observed with simple hysterectomy (LBA5511).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the standard treatment for the management of women with early stage cervical cancer is a radical hysterectomy, which involves the removal of the uterus and cervix, of course, but also the removal of parametrial tissue in upper vagina, which is what is associated with the greater morbidity of the procedure, as well as the potential complications and quality of life impacts issues on the bowel and bladder and sexual function. What we've noticed in retrospective studies is that the rate of parametrial infiltration in women meeting low risk criteria, and that means women with lesions under two centimeters and with limited stromal invasion of the cervix based on the preoperative MRI or on the LEEP and cone, these women meeting low risk criteria, in fact, have a very low rate of parametrial extension, approximately less than 1%. And so the question is, in those women with low risk disease, perhaps there is no need to do radical surgery, and perhaps we can in fact do simple hysterectomy, which would be less radical, with less morbidity and better quality of life. So that is the concept of the SHAPE trial. We wanted to confirm this finding in a prospective, randomized study. We have entered 700 women on this study. 350 had a radical hysterectomy, 350 had a simple hysterectomy, and of course, lymph node evaluation was performed as well. And so the primary endpoint of the study was the three-year pelvic relapse rate at three years. And so the main important findings of the studies shown that they were equivalent in terms of age, stage, histology and grade. Importantly, 45% of the women were age 50 or younger, so young women. And what we found importantly is that the pelvic recurrence rate is very low in both groups, in the range of 3%, which is quite low. And the extra pelvic recurrences were also very low. The three-year pelvic recurrence, which was the main point or endpoint of the study, was 2.52% in the simple hyst and 2.17% in the radical hysterectomy, so 0.35% difference. And that meant that we reached the non-inferiority of the simple hysterectomy compared to the radical hysterectomy in the study. So that's the first important endpoint. The second element is we looked at surgical complications and we found that women who had a radical hysterectomy had three times more bladder injuries, and nearly twice the number of urethral complications. Additionally, urinary incontinence and urinary retention were statistically worse in the radical hysterectomy group, and it persisted over time, meaning that it stayed longer. The third important element of the study was the quality of life. We evaluated with the questionnaires, quality of life and sexual health, and all the domains that we analyze, which is sexual function, pain, distress, et cetera, were all in favor of the simple hysterectomy group. So in summary, for patients with low risk, early stage cervical cancer, the SHAPE trial showed non-inferiority at the three-year pelvic relapse rate. We also show a better surgical complication profile with a simple hysterectomy and better quality of life in sexual health in simple hysterectomy group. And so we believe based on the results of the SHAPE trial, that the new standard of care for the management of women with early stage, low risk disease, carefully evaluated and selected, we think the simple hysterectomy is the new standard of care, and it goes in line with surgical deescalation.

Related Videos

Bladder Cancer

Arlene O. Siefker-Radtke, MD, on Metastatic Urothelial Carcinoma: New Data on Erdafitinib vs Chemotherapy From the THOR Study

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings showing that for patients with advanced or metastatic urothelial carcinoma and FGFR alteration who already had been treated with a PD-(L)1 inhibitor, erdafitinib significantly improved overall and progression-free survival, as well as overall response rate, compared with investigator’s choice of chemotherapy (LBA4619).

Kidney Cancer

Thomas E. Hutson, DO, PharmD, on RCC: Overall Survival Analysis of Lenvatinib, Pembrolizumab, and Sunitinib

Thomas E. Hutson, DO, PharmD, of Texas Oncology, discusses the 4-year follow-up results from the CLEAR study for patients with advanced renal cell carcinoma (RCC). The data showed that lenvatinib plus pembrolizumab continues to demonstrate clinically meaningful benefit vs sunitinib in overall and progression-free survival, as well as in overall and complete response rates, in first-line treatment (Abstract 4502).

Skin Cancer
Immunotherapy

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab

Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses phase I/II results on the efficacy of nivolumab with or without ipilimumab in patients with recurrent or metastatic Merkel cell carcinoma. The study found that, for this rare and aggressive skin cancer, nivolumab showed clinical activity in advanced disease. However, these results from CheckMate 358 do not suggest an additional benefit with ipilimumab added to nivolumab (Abstract 9506).

 

Gynecologic Cancers
Immunotherapy

Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab

Bobbie J. Rimel, MD, of Cedars-Sinai Medical Center, and Isabelle L. Ray-Coquard, MD, PhD, of Centre Léon Bérard and the University Claude Bernard Lyon Est, discuss findings from the COLIBRI trial, which showed that, for patients with cervical squamous cell carcinoma, neoadjuvant nivolumab plus ipilimumab is safe and orchestrates de novo immune responses. The 82.5% complete response rate for primary tumors 6 months after standard chemoradiation therapy suggests favorable clinical outcomes (Abstract 5501). 

Lymphoma

Nirav N. Shah, MD, on Mantle Cell Lymphoma: Follow-up Data on Pirtobrutinib in Pretreated Disease

Nirav N. Shah, MD, of the Medical College of Wisconsin, discusses the efficacy and safety of pirtobrutinib, a highly selective, noncovalent BTK inhibitor, studied for more than 3 years in the BRUIN trial. The results showed that the use of pirtobrutinib continues to have durable efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma and prior BTK inhibitor therapy. Responses were observed in patients with high-risk disease features, including blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations (Abstract 7514).

Advertisement

Advertisement




Advertisement